

Archit Organosys Limited

25 / 9 / A, 25 / 9 / B, Phase III, G.I.D.C., Naroda, Ahmedabad-382330. Gujarat, INDIA. Ph.: +91-79-22821154, 22800785

CIN: L24110GJ1993PLC019941

Date: August 05, 2021 AOL/46/2021-2022

To, BSE LimitedPhiroze Jeejeebhoy Tower,
Dalal Street, Mumbai – 400 001.

Dear Sir/Madam,

<u>Sub.</u>: Statement of Deviation in utilization of funds raised through Preferential Convertible warrant as required under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

With reference to the captioned subject matter, attached herewith the details of utilization of funds till 30^{th} June, 2021.

Kindly acknowledge the receipt of the same.

For Archit Organosys Limited

Kandarp Amin

Chairman and Whole Time Director

Encl: As above

Statement of Deviation / Variation in utilization of funds raise						
	Archit Organosys Limited					
Name of listed entity	ž i					
Mode of Fund Raising	Preferential issue of Convertible					
	Warrants					
Date of Raising Funds	13/10/2020					
Amount Raised	Issued size of Rs. 550 lakh	1				
	(55,00,000 number of warrants of					
	Rs. 10 each). Upon application, total					
	Rs. 137.5 lakh consisting of					
	55,00,000 warrant @ Rs 25% per					
	share of Rs. 10/- each has received.					
	Amount has received as per SEBI					
	(ICDR) Regulations, 25% of issue					
	price i.e. Rs. 2.5 per warrant has					
	been received upon allotment of					
	equity shares upon conversion of					
	warrants.					
	During this quarter, 20,00,000					
	warrants have been converted into					
	equity shares on 31/05/2021 and					
	balance 35,00,000 warrants have					
	been converted into equity shares					
	on 23/06/2021.					
Report filed for Quarter ended	30 th June, 2021					
Monitoring Agency	Not applicable					
Monitoring Agency Name, if applicable	-					
Is there a Deviation / Variation in use of funds raised	No					
If yes, whether the same is pursuant to change in						
terms of a contract or objects, which was approved	-					
by the shareholders						
If Yes, Date of shareholder Approval	.=					
Explanation for the Deviation / Variation	-					

Comments of the Audit Committee after review Comments of the auditors, if any Objects for which funds have been raised and where there has been a deviation, in the following table	-					
Original Object	Modified Object, if any	Origin al Allocati on	Modified allocation, if any	Funds Utilised	Amount of Deviation/ Variation for the quarter according to applicable object	Remarks if any
The proceeds of the proposed issue will be utilized for any one or in combination with any one or more of the purposes such as to augment the fund for to augment the net worth of the Company and to form a capital base for business growth, to meet the long term fund requirements of the Company, to repay the debt of the Company for capital expenditure to be incurred for expansion and new product addition, to meet working capital requirements arose due to loss, to improve the capital structure and for general corporate purpose-	N.A	Issue Size: Rs. 550 Lakh Amount received: Rs. 550 Lakh	N.A	Rs. 549.93	N.A	Amount is received as per SEBI (ICDR) Regulations, 25% of issue price i.e. Rs. 2.5 per warrant has been received at the time of conversion of warrants. During this quarter, the balance money has received and converted warrant into equity Share.

Date: 05/08/2021

ATWEDABAD EN AMEDABAD EN AMEDA

Kandarp Amin Chairman and Whole Time Director